- Home
- AKBA vs OFLX Comparison
AKBA vs OFLX Comparison
Compare AKBA & OFLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKBA
- OFLX
- Stock Information
- Founded
- AKBA 2007
- OFLX 1975
- Country
- AKBA United States
- OFLX United States
- Employees
- AKBA N/A
- OFLX N/A
- Industry
- AKBA Biotechnology: Pharmaceutical Preparations
- OFLX Industrial Specialties
- Sector
- AKBA Health Care
- OFLX Industrials
- Exchange
- AKBA Nasdaq
- OFLX Nasdaq
- Market Cap
- AKBA 336.2M
- OFLX 374.3M
- IPO Year
- AKBA 2014
- OFLX 2005
- Fundamental
- Price
- AKBA $2.14
- OFLX $31.49
- Analyst Decision
- AKBA Strong Buy
- OFLX
- Analyst Count
- AKBA 3
- OFLX 0
- Target Price
- AKBA $6.50
- OFLX N/A
- AVG Volume (30 Days)
- AKBA 4.5M
- OFLX 29.1K
- Earning Date
- AKBA 05-08-2025
- OFLX 05-05-2025
- Dividend Yield
- AKBA N/A
- OFLX 4.39%
- EPS Growth
- AKBA N/A
- OFLX N/A
- EPS
- AKBA N/A
- OFLX 1.78
- Revenue
- AKBA $160,180,000.00
- OFLX $101,681,000.00
- Revenue This Year
- AKBA $22.50
- OFLX N/A
- Revenue Next Year
- AKBA $43.23
- OFLX N/A
- P/E Ratio
- AKBA N/A
- OFLX $16.25
- Revenue Growth
- AKBA N/A
- OFLX N/A
- 52 Week Low
- AKBA $0.80
- OFLX $28.12
- 52 Week High
- AKBA $2.89
- OFLX $68.50
- Technical
- Relative Strength Index (RSI)
- AKBA 59.49
- OFLX 41.15
- Support Level
- AKBA $1.52
- OFLX $28.12
- Resistance Level
- AKBA $2.16
- OFLX $31.14
- Average True Range (ATR)
- AKBA 0.15
- OFLX 1.68
- MACD
- AKBA 0.04
- OFLX -0.08
- Stochastic Oscillator
- AKBA 96.88
- OFLX 46.42
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
About OFLX Omega Flex Inc.
Omega Flex Inc is a manufacturer of flexible metal hoses, which is used in a variety of ways to carry gases and liquids within their particular applications. Omega sells its products under the TracPipe, CounterStrike, DoubleTrac, DEF-Trac and MediTrac brands. It serves various markets which include construction, manufacturing, transportation, petrochemical, pharmaceutical, and other industries. Geographically Omega Flex, Inc operates in the United States.